Development of a Rapid and Inexpensive Assay for Detecting a Surrogate Genetic Polymorphism of HLA-B*58:01: A Partially Predictive but Useful Biomarker for Allopurinol-related Stevens-Johnson Syndrome/toxic Epidermal Necrolysis in Japanese
Authors:
- Jun NishikawaJNJun Nishikawa
- Nahoko KaniwaNKNahoko Kaniwa
- Emiko SugiyamaESEmiko Sugiyama
- Tomoko KoizumiTKTomoko Koizumi
- Kouichi KuroseKKKouichi Kurose
- Masahiro TohkinMTMasahiro Tohkin
- Yoshiro SaitoYSYoshiro Saito
- 1 January 2012
- journal article
- research article
- Published by Japanese Society for the Study of Xenobiotics in Drug Metabolism and Pharmacokinetics
- Vol. 27 (4) , 447-450
Abstract
Allopurinol-induced Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) is strongly associated with HLA-B*58:01 in various populations including Japanese. We demonstrated that several single nucleotide polymorphisms (SNPs) around the HLA region on chromosome 6 were strongly linked with HLA-B*58:01 in a previous study using Japanese allopurinol-related SJS/TEN patients. Their very strong linkage suggests that these SNPs could be used as surrogate biomarkers to find carriers of HLA-B*58:01 to avoid these serious adverse effects. In the present study, to expedite the application of this pharmacogenomic information to the proper usage of allopurinol in a clinical situation, we developed a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay for the genotyping of rs9263726 in the psoriasis susceptibility 1 candidate 1 (PSORS1C1) gene, which is in absolute linkage disequilibrium (r(2) = 1, D' = 1) with HLA-B*58:01. The developed PCR-RFLP assay using FokI restriction enzyme was able to detect three different genotypes, GG, GA, and AA of rs9263726 robustly, and thus to find HLA-B*58:01 carriers. This robust and inexpensive assay would be useful for pre-screening the subjects with HLA-B*58:01, a genetically high risk factor for allopurinol-induced SJS/TEN.Keywords
This publication has 14 references indexed in Scilit:
- A whole-genome association study of major determinants for allopurinol-related Stevens–Johnson syndrome and toxic epidermal necrolysis in Japanese patientsThe Pharmacogenomics Journal, 2011
- Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in KoreansPharmacogenetics and Genomics, 2011
- Pharmacogenetics of cutaneous adverse drug reactionsThe Journal of Dermatology, 2011
- Prediction of Severe Adverse Drug Reactions Using Pharmacogenetic BiomarkersDrug Metabolism and Pharmacokinetics, 2010
- Strong association between HLA-B*5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai populationPharmacogenetics and Genomics, 2009
- HLA-B Locus in Japanese Patients with Anti-Epileptics and Allopurinol-Related Stevens–Johnson Syndrome and Toxic Epidermal NecrolysisPharmacogenomics, 2008
- A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugsPharmacogenetics and Genomics, 2008
- HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinolProceedings of the National Academy of Sciences, 2005
- Correlations Between Clinical Patterns and Causes of Erythema Multiforme Majus, Stevens-Johnson Syndrome, and Toxic Epidermal NecrolysisArchives of Dermatology, 2002
- Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990–1992): Structure and results of a population-based registryJournal of Clinical Epidemiology, 1996